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Abstract
Introduction and hypothesis Our aim was to evaluate clinical-
ly relevant long-term outcomes of transvaginal mesh or native
tissue repair in women with recurrent pelvic organ prolapse
(POP).
Methods We performed a 7-year follow-up of a randomized
controlled trial on trocar-guided mesh placement or native
tissue repair in women with recurrent POP. Primary outcome
was composite success, defined as absence of POP beyond the
hymen, absence of bulge symptoms, and absence of
retreatment for POP. Secondary outcomes were adverse
events, pain, and dyspareunia. Multiple imputation was used
for missing data of composite success and pain; estimates are
presented with 95% confidence intervals (CI).
Results Between August 2006 and July 2008, 194 women
were randomized; 190 underwent surgery. At 7 years, 142
(75%) were available for analysis, of whom, the primary
outcome could be calculated in 127. Composite success
was 53% (95% CI 41, 66) for mesh and 54% (95% CI 42,
65) for native tissue. Repeat surgery for POP was 25% for
mesh and 16% for native tissue (difference 9%; 95% CI
−5, 23) and occurred in untreated compartments in the
mesh group and treated compartments in the native tissue
group. Mesh exposure rate was 42%; pain with mesh 39%
and native tissue 50% (difference − 11%, 95% CI −27, 6);
dyspareunia with mesh 20% and native tissue 17% (dif-
ference 3%, 95% CI −9, 17).
Conclusions Seven-year composite success rates appeared
similar for mesh and native tissue. Mesh did not reduce
long-term repeat surgery rates due to de novo POP in
nonmesh-treated vaginal compartments. Mesh exposure rates
were high, though significant differences in pain and
dyspareunia were not detected.
Clinical trial registration . Cl inicalTrials .gov,
NCT00372190.
Keywords Long-termoutcome .Mesh .Native tissue . Pain .
Pelvic organ prolapse . Surgery
Introduction
The 10-year rate of repeat surgery for pelvic organ pro-
lapse (POP) and urinary incontinence (UI) is as high as
17% [1]. Searching for more effective treatments and in-
spired by favorable results of synthetic mesh use in ingui-
nal hernia and stress urinary incontinence (SUI) surgery,
mesh was introduced in vaginal POP surgery [2–4]. The
commercial introduction of the relatively easy to use mesh
Preliminary data were presented at the 40th annual scientific meeting of
the International Urogynecological Association in Nice, France, 11
June 2015.
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kit in 2005 has accelerated worldwide use of synthetic
mesh, while 1-year outcomes of the first prospective ob-
servational study were first published in 2007 [5]. An
increasing number of adverse events, including mesh ex-
posure, pain, and dyspareunia led to the US Food and
Drug Association (FDA) Public Health Notifications of
2008 and 2011, with the intention to increase public
awareness of risks associated with surgical mesh for
transvaginal repair of POP [6]. Subsequent class action
lawsuits occurred and gradually led to removal of many
vaginal mesh products from the market.
A limited number of randomized clinical trials (RCT) com-
pared short-term safety and efficacy of nonabsorbable mesh
with native tissue repair [7]. Long-term data of those trials are
lacking, though sorely needed. This RCT focused on patients
with recurrent POP and compared a trocar-guided nonabsorb-
able tension-free vaginal mesh (TVM) with native tissue re-
pair [8]. At 12 months, anatomic failures after TVM appeared
fewer than native tissue repair, but symptom decrease and
quality of life (QoL) improvement were similar between
groups [8].
The study reported focused on the long-term follow-up
of that RCT, with the primary aim being comparison of
long-term composite success (a combination of anatomy,
functional success, and absence of retreatment) 7 years
after surgery. The secondary aim was to describe long-
term adverse events, with particular focus on pain and
dyspareunia.
Materials and methods
The original trial was performed in 13 centers in
The Netherlands between August 2006 and July 2008
(www.clinicaltrials.gov, NCT00372190). Patients with
recurrent POP were 1:1 randomized between a first-
generation nonabsorbable TVM (anterior, posterior or to-
tal) (Prolift™, Ethicon, Somerville, NJ, USA) and con-
ventional vaginal native tissue repair. Repairs comprised
anterior or posterior colporrhaphies; a Manchester
Fothergill procedure; or vaginal hysterectomy with high
uterosacral ligament suspension, sacrospinous ligament
suspension, or a combination. Details regarding design,
randomization, sample size, surgical interventions, and
1-year outcomes have previously been published [8].
Extended follow-up at 7 and 10 years was approved by
the Medical Ethics Committee, region Arnhem-Nijmegen,
The Netherlands, on 28 April 2014 under no. NL46834.
0 9 1 . 1 4 a n d r e g i s t e r e d i n c l i n i c a l Tr i a l s . g o v,
NCT00372190. Informed consent was obtained prior to
inclusion in the extended follow-up.
All participants of the index study received a letter to
inform them on the intended long-term follow-up. Two
weeks later, a research nurse approached those women
by telephone and scheduled an outpatient clinic appoint-
ment if they agreed to participate. One independent exam-
iner (AD), a subspecialist in urogynecology, was blinded
to the index procedures and performed all interviews and
physical examinations at the original study sites.
Participants completed the same validated urogynecologic
questionnaires as were used at baseline and 1 year in the
index study: Global Impression of Improvement question-
naire (PGI-I), visual analog scale (VAS), EuroQol-5D
(EQ-5D), Urogeni ta l Dis t ress Inventory (UDI) ,
Defecatory Distress Inventory (DDI), Incontinence
Impact Questionnaire (IIQ), and the short form of the
Pelvic Organ Prolapse Urinary Incontinence Sexual
Questionnaire (PISQ-12) [9–12]. The UDI, DDI, and IIQ
are each subdivided into five domains, with subscales
ranging from 0 to 100 and higher scores indicating more
bother and worse QoL. Scores on 12 individual questions
of the PISQ-12 ranged from 0 to 4 on a 5-point Likert
scale, and total scores range from 0 (poorest) to 48 (best)
for sexual function [13].
Subjective prolapse symptoms were considered present if a
patient answered affirmatively to the question: Do you see or
do you feel a vaginal bulge? Pain was considered present if a
patient answered affirmatively to the question: Do you expe-
rience pain in the lower abdomen or genital region?
Dyspareunia was considered present if a patient answered
affirmatively to the question: Do you experience pain during
intercourse? The degree of bother caused by dyspareunia was
registered using a 4-point Likert scale (1, not at all bothered; 4
bothered quite a bit). SUI was considered present if a patient
answered affirmatively to the question: Do you experience
involuntary urine loss during physical exercise, coughing, or
sneezing? De novo SUI was considered present if the partic-
ipant had no SUI according the baseline questionnaire but
answered affirmatively at 7 years or had received treatment
for SUI after the trial’s index surgery within the 7-year follow-
up.
Pain was assessed with a 10-point VAS, where 0 de-
noted no pain and 10 the worst imaginable. Prior to
physical examination, women were requested to undergo
two VAS for pain: one at rest and one during physical
activity.
Physical examination consisted of POP staging using
the Pelvic Organ Prolapse Quantification (POP-Q) system
[14]. A thorough examination of the vagina was per-
formed to objectify any visible or palpable mesh expo-
sure, prominence, or excessive scarring of the vaginal
epithelium and pain during vaginal examination [15].
Participants were asked to rate pain intensity during vag-
inal examination on another VAS. The examiner also
completed a VAS of subjective impression she had of pain
experienced by the patient, blinded to the patient’s score,
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and was not informed on this specific assessment prior to
the examination.
In contrast with the primary outcome at 1 year, defined
as an anatomic failure in treated vaginal compartments,
the primary outcome of the study reported here was com-
posite success, defined as a combination of absence of
POP beyond the hymen in a treated or nontreated com-
partment, absence of bulge symptoms, and absence of
retreatment for POP in a treated or nontreated compart-
ment [16]. If no POP beyond the hymen was noted on
POP-Q examination but the questionnaire was missing, a
composite outcome could not be calculated. This also ap-
plied if the questionnaire noted absence of bulge symp-
toms, but the POP-Q was missing. If, however, the ques-
tionnaire noted bulge symptoms, but the POP-Q was
missing, the composite outcome was considered a failure,
as was POP beyond the hymen without a questionnaire.
Any registered retreatment for POP, with or without fol-
low-up, was considered a failure. Retrospectively, com-
posite success rates were calculated for all participants at
the 1-year follow-up and used for comparison over time.
Secondary outcomes were anatomic recurrences overall
and failures per treated vaginal compartment at 7 years,
defined as POP stage ≥ II, POP > hymen, de novo SUI,
surgery-related complications for mesh, pain perception,
and dyspareunia. Descriptive statistics with numbers, per-
centages, and risk differences with 95% CI were used to
summarize baseline characteristics and primary and sec-
ondary outcomes. The 95% CI for differences between
median values was estimated with the Hodges–Lehmann
estimator [17].
To account for missing data of women who were alive
but did not attend the 7-year follow-up visit, a multiple
imputation approach was used for composite success and
UDI domain of pain. Analyses were performed using the
combination of 50 data sets generated with the fully con-
ditional method (chained equations) for imputation of
missing values. Values imputed for pain <0 or >100 were
truncated to 0 or 100, and composite success was imputed
as a binary variable. Missing data of women who died
during the 7-year follow-up were not imputed in the main
analysis, but were imputed as failures in a sensitivity anal-
ysis of composite success. After multiple imputation,
composite success was analyzed using a binomial distri-
bution, an identity link, and covariate treatment group.
UDI domain pain was analyzed using a linear model, with
covariate treatment group and pain at baseline.
Analysis was according the intention-to-treat princi-
ple. Statistical analyses were performed using SPSS
Statistics for Windows, version 22.0 and analyses of
pain and composite success with the STAT package
(SAS® statistical software, version 9.4, SAS Institute
Inc., Cary, NC, USA).
Results
One hundred and ninety-four women were randomized in
the index trial between August 2006 and July 2008, of
whom 190 underwent surgical treatment. In this 7-year
follow-up, 142 (75%) women were available for analysis
(Fig. 1). Based on the selection criteria described in the
Materials and Methods section, a composite outcome
could be calculated of 127 participants. Of 15 women data
were incomplete, so a composite outcome could not be
calculated.
Characteristics of participants in the 7-year follow-up
were similar between groups at baseline (Table 1), includ-
ing post hoc calculated composite success rates at 1 year
(76%, 95% CI 62, 85 vs. 74%, 95% CI 62, 84 for mesh
and native tissue, respectively). Some differences existed
between responders and nonresponders in the study re-
ported here: responders were significantly younger and
had lower POP stages at the time of index surgery and
more often had reported dyspareunia at baseline. General
health scores (VAS, EQ-5D) at 1-year were higher among
responders (Table 2).
The primary outcome, overall composite success at
7 years, was similar between women treated with mesh
or native tissue (53%; 95% CI 41, 66 vs. 54%; 95% CI
42, 65; Table 3). These results were similar to the per-
centages estimated after applying multiple imputations
for missing data. Success rates were slightly lower after
imputing failures for missing data of deceased patients,
but the difference between groups remained negligible.
Between 1 and 7 years, composite success rates de-
creased by 22% for mesh and 20% for native tissue
(Table 3).
Repeat surgery rates for POP were somewhat different
between groups (Table 3). In the mesh group, repeat sur-
gery was performed in 14/56 cases. Nine times an addi-
tional mesh was inserted (8 vaginally and 1 abdominally),
and in 13 cases, surgery was in the non-mesh-treated
compartment. In contrast, repeat surgery in the native tis-
sue group occurred in 11/69 cases, and more frequently in
the treated vaginal compartment. Nine times a mesh was
inserted in this group (8 vaginally and 1 abdominally). In
the mesh group, there were fewer anatomic failures (POP
≥ II) in the treated anterior vaginal compartment com-
pared with in the native tissue group. Bulge symptoms
and patient global impressions of improvement were not
significantly different between groups (Table 7,
BAppendix 3^).
At 7 years, there was no significant difference between
groups in terms of de novo SUI (19% mesh, 12% native
tissue) (Table 8 "Appendix 4"). The cumulative prevalence
of mesh exposure at 7 years was 42% in the mesh group,
with 13% repeat surgeries for mesh exposure in this 7-
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year period (Table 8, BAppendix 4^ ). Ten patients (45%)
with exposure experienced no symptoms; 12 patients
(55%) reported pain. In 77% (17 patients), exposure was
<1 cm (Addendum, Table 5, "Appendix 1^ ). In the native
tissue group, four patients (6%) had exposure: two due to
mesh placement after the index surgery, one due to a
Prolene suture used for sacrospinous ligament fixation
and one after midurethral sling inserted after index
surgery.
Data on pain and dyspareunia assessed by interview,
self-completed questionnaires, and during gynecological
examinations are shown in Table 8, BAppendix 4^ .
Estimates of patient self-reported pain scores (UDI) with
and without multiple imputation were not significantly
different between groups (Table 4). Per-protocol analysis
did not reveal a significant difference either between mesh
or native tissue repair (Table 4). Provoked pain during
gynecological examination, however, was significantly
more prevalent in the mesh group (Table 8, BAppendix
4^ ).
Changes in health-related QoL scores between baseline
and 7 years are shown in Table 6, BAppendix 2^; neither group
showed significant changes over time in sexual function mea-
sured with the PISQ-12.
Discussion
The long-term follow-up of this multicenter RCT showed
similar composite success rates 7 years after TVM or na-
tive tissue repair in women with recurrent POP. Women
treated with mesh often developed POP in a non-mesh-
treated vaginal compartment with the need for repeat sur-
gery. In contrast, after native tissue repair, significantly
more recurrences were seen in the treated compartments.
This phenomenon has been reported for the 1-year follow-
up [18, 19].
Compared with a composite success of 84% at 5-year
follow-up in a French cohort study using the same mesh
kit, composite success of 53% in our mesh group was
considerably lower [20]. In the French study, all patients
received total vaginal mesh that treated all three vaginal
compartments. Subanalysis of total mesh implantations in
our study showed a composite success rate of 73% at
7 years, comparable with French results. One should con-
sider, however, that total vaginal mesh implants are asso-
ciated with a significantly higher risk of mesh exposure
[21]. A remarkable finding in our study was the signifi-
cant decrease between post hoc calculated composite suc-
cess rates at 1 year and composite success rates at 7 years
Randomized 
(n=194)
Allocated to tension-free 
vaginal mesh 
(n=95)
Allocated to native 
tissue repair
(n=99)
Did not undergo surgery (n=2)
  Refused: 1
  Died: 1
Underwent allocated surgery 
(n=93)






Did not undergo surgery (n=2)
  Refused: 2
Analyzed (n=90)
  • Anatomic analysis: 83
  • Functional analysis: 84
    ◦ Questionnaires only: 7
Analyzed (n=96)
  • Anatomic analysis: 84
  • Functional analysis: 88






  • Composite outcome: 58
  • Anatomic analysis: 53
  • Functional analysis: 66
    ◦ Questionnaires only: 8
Analyzed (n=78)*
  • Composite outcome: 69
  • Anatomic analysis: 67
  • Functional analysis: 76
    ◦ Questionnaires only: 9
Excluded (n=19)
  Died: 6
  Lost to follow-up: 13
    Address irretrievable: 1
    Refused, reasons: 12
      Unknown: 6
      Health-related: 6
Excluded (n=27)
  Died: 6
  Lost to follow-up: 21
    Address irretrievable: 6
    Refused, reasons: 15
      Unknown: 7




Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart of randomization and follow-up. *Includes those lost to follow-up at 1 year
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in both treatment groups. Increasing failure rates have
a l s o b e e n r e po r t e d 7 y e a r s a f t e r a b dom i n a l
sacrocolpopexy [22].
For the long-term follow-up, we used a primary out-
come different from that used in the index study. Barber
et al. demonstrated in 2009 that patient impression of
improvement was associated with absence of vaginal
bulge symptoms [16]. The use of a composite outcome
(combining anatomic and functional success, in the ab-
sence of retreatment) is therefore considered clinically
more relevant and is in accordance with International
Urogynecological Associat ion and Internat ional
Continence Society (IUGA–ICS) recommendations [16,
23].
The mesh exposure rate increased substantially over
time, from 17% at 1 year to 42% at 7 years [8] There
are a number of possible explanations. The mesh kit used
consisted of relatively large pieces of nonabsorbable mesh
(anterior 10 × 13 cm, posterior 7 × 16 cm) with relatively
high weight of 45 g/m2. The total amount and weight of
implanted mesh are correlated with the risk of exposure
[21, 24–26]. Furthermore, 22 surgeons performed index
surgeries, and although they were all considered experi-
enced, they had their own learning curves and levels of
experience [21]. An increase in exposure rates over the
years has also been described in the extended follow-up
of abdominal sacrocolpopexy [22].
In the media and according to lawsuits, there are nu-
merous reports of patients with chronic pelvic pain and
dyspareunia after mesh insertion [27]. We used various
tools to assess pain and dyspareunia: patient self-
completed questionnaires, doctor interviews, and VAS
scores. We observed nonsignificant differences in ratings
of pain and dyspareunia between groups. We hypothesize
that repeat POP surgery itself may cause pain, and pain
may not be solely caused by the mesh.
Change in primary outcome is a limitation of this
study, since the index study was powered on anatomic
success and not on subjective outcomes, which probably
would have needed a larger sample size. Loss of partici-
pants in long-term follow-up studies is inevitable, partic-
ularly when considering the advanced mean age of the
Table 1 Characteristics of
responders (participants in the 7-
year follow-up) by treatment group




Age at time of surgery (years) 60.9 ± 9.0 62.4 ± 10.2 −1.5 (−5.1, 1.7)
Age at follow-up (years) 67.1 ± 8.9 68.8 ± 9.9 −1.7 (−5.1, 1.7)
Follow-up (months) 84 (65–98) 84 (65–99) 0 (−3.0, 3.0)
Parity (n) 2 (1–6) 2 (1–5) 0 (0, 0)
BMI (kg/m2) 26.4 ± 4.1 26.8 ± 4.3 −0.4 (−2.0, 1.1)
Prior number of POP surgeries 1 (1–3) 1 (1–3) 0 (0, 0)
Prior number of treated vaginal
compartments
2 (1–3) 2 (1–3) 0 (0, 0)
POP-Q stage at time of surgery
• Stage II 33 (57) 36 (52) 5 (−13, 22)
• Stage III 24 (41) 31 (45) −4 (−21, 14)
• Stage IV 1 (2) 2 (3) −1 (−6, 4)
Pain at baseline
• Yes 26/55 (47) 35/58 (60) −13 (−31, 5)
• UDI pain score 26.1 (24.2, 28.0) 28.8 (26.3, 31.3) −2.6 (−10.9,
5.6)
Dyspareunia at baseline
• Moderate to quite a bit 11/53 (21) 15/58 (26) −5 (−21, 11)
• Yes 18/53 (34) 27/58(46) −12 (−31, 6)
Composite success and pain score at 1 year
• Composite success; n [%: (95% CI)] 40/53 [76: (62, 85)] 43/58 [74: (62, 84)] 2 (−15, 18)
• UDI Pain score; n (CI) 13.2 (11.4, 15.0) 15.1 (13.5, 16.7) −1.8 (−8.5, 4.9)
Data presented as mean ± standard deviation (SD), median (range), n (%), I [%: (95% CI)], % (95% CI), or mean
(95% CI)
BMI body mass index, POP-Q Pelvic Organ Prolapse Quantification system, UDI pain score urodynamic pain
score, 0–100, CI confidence interval
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target group. Restricting the analysis to patients who com-
pleted the 7-year follow-up provides valid results if miss-
ing data are completely random; otherwise, it generates
potentially biased results. Use of the multiple imputation
technique, by which imputations of missing values are
based on other known patient characteristics, leads to un-
biased results with correct standard errors [28]. However,
although this approach removes bias, it does not add pow-
er to the study. Data should therefore be interpreted with
caution, since the study lacks power on negative out-
comes. Furthermore, continuous negative media attention
may have influenced the way participants responded to
the questionnaires.
Although the mesh kit was withdrawn from the mar-
ket in 2013, long-term data are still relevant to many
patients, their doctors, and other stakeholders, e.g., health
care inspectorates. According to sales information by
Johnson & Johnson, >220,000 mesh kits were sold
worldwide, in addition to comparable kits sold by other
companies.
Strengths of this study are the design (multicenter
RCT), systematic long-term follow-up, physical exam
by one independent observer (blinded to the index pro-
cedures), and the high response rate. Furthermore, the
extensive assessment of pain and dyspareunia with data
at both baseline and 7 years after index surgery is
unique. The 2006 American College of Obstetricians
and Gynecologists Committee Opinion on Ethical
Guidelines in Innovative Practice state that: Bwithout
adequate data on risks and benefits of new treatments,
patients are unable to provide truly informed consent^
[29]. Our long-term evaluation may contribute to these
guidelines and offer support when counseling patients
with recurrent POP, specifically regarding long-term
risks of recurrence, pain, and dyspareunia following
vaginal mesh kit surgery for POP.
Table 2 Characteristics of
responders versus nonresponders







Age at time of surgery (years) 61.6 ± 9.7 67.7 ± 10.4 −6.1* (−9.2, −3.1)
Parity 2 (1–6) 3 (0–5) 0 (0, 1.0)
BMI (kg/m2) 26.6 ± 4.2 26.9 ± 4.1 −0.3 (−1.6, 1.1)
Prior number of POP surgeries 1 (1–3) 1 (1–2) 0 (0, 0)
Prior number of treated vaginal compartments 2 (1–3) 2 (1–3) 0 (0, 0)
POP-Q stage at time of surgery
• Stage II 69 (54.3) 21 (33.3) 21.0* (6.5, 35.5)
• Stage III 55 (43.3) 42 (66.7) −23.4* (−37.8, −8.9)
• Stage IV 3 (2.4) 0 2.4 (−0.3, 5.0)
Pain at baseline
• Yes 61/113 (54.0) 23/48 (47.9) 6.1 (−10.8, 22.9)
• UDI pain score 28.7 (26.9, 30.4) 23.4 (19.8, 27.0) 5.3 (−3.7, 14.3)
Dyspareunia at baseline
• Moderately to quite a bit 26/111 (23.4) 3/45 (6.7) 16.8* (6.0, 27.5)
• Yes 45/111 (40.5) 4/45 (8.9) 31.7* (19.3, 44.0)
Outcomes at 1-year follow-up
Composite success 83/111 (74.8) 31/43 (72.1) 2.6 (−12.9, 18.3)
Overall POP-Q ≥ stage II 66/115 (57.4) 23/52 (44.2) 13.2 (−3.1, 29.4)
PGI-I (much to very much better) 78/108 (72.2) 31/49 (63.3) 8.9 (−6.9, 24.9)
VAS EQ-5D 78.2 ± 14.6 72.4 ± 20.3 5.8* (0.2, 11.5)
Exposure 9/114 (7.9) 5/52 (9.6) −1.7 (−11.1, 7.7)
UDI pain score 14.3 (13.1, 15.5) 13.8 (10.4, 17.1) 0.5 (−6.9, 7.9)
Dyspareunia
• Moderately to quite a bit 18/115 (16.2) 3/47 (4.7) 9.3 (−0.4, 18.9)
• Yes 35/115 (30.4) 8/46 (17.4) 13.0 (−0.8, 26.9)
Data presented as mean ± standard deviation (SD), median (range), n (%), or mean (95% CI)
BMI body mass index, PGI-I Patient Global Impression of Improvement, VAS EQ-5D perceived health condition
according visual analog scale, EuroQuol-5D questionnaire (100 = best imaginable, 0 = worst imaginable), UDI
pain score urodynamic pain score, 0–100, CI confidence interval
*This difference would be statistically significant if tested at a significance level of 0.05
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Findings in this study strengthen the necessity of long-term
observations on safety and efficacy when surgical devices are
used in POP surgery. In every woman with recurrent POP, a
native tissue repair can be reconsidered, preferably based on a
prediction model [30]. Only if native tissue repair is expected
to be inferior should a smaller piece of lightweight vaginal
Table 4 Pain at 7 years
Mesh Native tissue Risk difference (95%CI)
Indicated on questionnaire
(intention-to-treat analysis)
Questionnaires (n) 66 72
Pain: yes 26 (39) 36 (50) −11 (−27, 6)
• UDI pain score 16.2 (16.2, 16.2) 20.2 (18.6, 21.8) −4.1 (−11.3, 3.1)
• Estimated pain score after MI 17.8 (13.0, 22.6) 18.9 (14.6, 23.3) −1.1 (−7.5, 5.2)
Having sexual intercourse 30 (46) 30 (42) 4 (−13, 20)
Indicated on questionnaire
(per-protocol analysis)
Questionnaires (n) 72 66
Pain: yes 29 (40) 33 (50) −10 (−26, 7)
Data presented as n (%) or mean (95% CI)
MI multiple Imputation, UDI pain score Urogenital Distress Inventory, range 0–100, CI confidence interval
At 7 years, 9 native tissue patients received mesh: 8 were transvaginal mesh (TVM), of whom 6 completed the
questionnaire
Table 3 Primary and secondary




• Participants, n [% (95% CI)] 31/58 [53 (41, 66)] 37/69 [54 (42, 65)] −1 (−18, 17)
• Estimated % (95% CI) after MIa 53 (40, 66) 54 (43, 65) −1 (−18, 16)
• Estimated % (95% CI) after MIb 51 (38, 64) 50 (39, 61) −1 (−17, 16)
Change in composite success between 1 and 7 years
% (95% CI) of 7-year participant data −22 (−39, −5) −20 (−37, −4) 2 (−12, 16)
Composite failures 27/58 (47) 32/69 (46) 1 (−17, 18)
• Failure in treated compartment 3/58 (5) 18/69 (26) −21* (−33, −9)
• Failure in untreated compartment 17/58 (29) 5/69 (7) 22* (9, 35)
• Failure due to bulge but no POP > hymen 5/58 (9) 1/69 (1) 7 (−1, 15)
• Failure due to bulge (questionnaire only) 2/58 (3) 8/69 (12) −8 (−17, 1)
Secondary outcomes
Reoperation for POP 14c/56 (25) 11d/69 (16) 9 (−5, 23)
• In treated compartment 1 (7) 9 (82) −75* (−100, −48)
• In nontreated compartment 13 (93) 2 (18) 75* (48, 100)
POP ≥ stage II 28/53 (53) 47/67 (70) −17 (−35, 0)
Reoperation for POP and/or POP-Q ≥ stage II 35/56 (62) 53/69 (77) −15 (−30, 2)
POP > hymen 8/53 (15) 12/67 (18) −3 (−16, 10)
POP > hymen, no sensation of bulge 4/53 (8) 7/67 (10) −3 (−13,7)
Reoperation for POP and/or POP > hymen 22/58 (38) 23/69 (33) 5 (−12, 21)
Subjective outcomes
• Sensation of bulge 14/66 (21) 17/76 (22) −1 (−14,19)
• PGI-I (much to very much better) 42/60 (70) 41/72 (57) 13 (−3, 29)
Data presented as n (%), n [% (95% CI)], or % (95% CI)
POP pelvic organ prolapse, PGI-I Patient Global Impression of Improvement,MImultiple imputation of missing
data,
a MI excluding deceased patients
b MI with failures for missings of deceased patients
c Nine patients received another mesh
d Nine patients received mesh
*This difference would be statistically significant if tested at a significance level of 0.05
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mesh or an abdominal mesh procedure be considered, but only
if performed by experienced surgeons [31]. It is of utmost
importance to counsel every woman planning to undergo
any kind of POP surgery on the risks of pain and dyspareunia,
particularly in case of repeat surgery.
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Appendix 1
Table 5 Addendum. Classification of complications by category and grades of pain at clinical visit 7 years following surgery
Mesh (n = 53) Native tissue (n = 67) Risk difference (95% CI)
Any complication 40 (75) 39 (58) 17.3%* (0.7, 33.8)
Category Grades of pain Asymptomatic Symptomatic Asymptomatic Symptomatic
12 (23) 28 (53) 5 (8) 34 (51)


















Data presented as numbers (%)
Category: (1) Vaginal, no epithelial separation; includes prominence or excessive scarring, (2) vaginal epithelial separation ≤1 cm, (3) vaginal epithelial
separation ≥1 cm
Grades of pain: (a) Asymptomatic or no pain, (b) provoked pain only (during vaginal examination), (c) pain during sexual intercourse, (d) pain during
physical activities, (e) spontaneous pain
*This difference would be statistically significant if tested at a significance level of 0.05
854 Int Urogynecol J (2018) 29:847–858
Appendix 2
Table 6 Changes in health-
related quality of life and sexual
function between baseline and
7 years
Mesh (n 66) Native tissue (n 76) Difference (95% CI)
Mean change in UDI domain scores
UDI Overactive bladder −6.3 ± 25.0 −3.4 ± 27.5 2.9 (−6.8, 12.6)
Incontinence 3.3 ± 26.0 1.3 ± 27.0 −2.0 (−11.5, 7.5)
Obstructive micturition −6.0 ± 27.6 −4.8 ± 29.9 1.2 (−9.0, 11.5)
Pain −7.8 ± 24.4 −12.4 ± 31.2 −4.6 (−14.8, 5.5)
Genital prolapse −41.5 ± 31.8 −41.9 ± 37.3 −0.4 (−12.7, 11.9)
Mean change in DDI domain scores
DDI Constipation −0.3 ± 17.8 −2.4 ± 16.8 −2.1 (−8.4, 4.2)
Obstructive defecation 2.1 ± 18.4 −5.2 ± 19.1 −7.3 (−14.2, 0.5)
Pain −5.8 ± 17.6 −0.8 ± 19.6 5.0 (−1.5, 11.7)
Fecal incontinence 4.5 ± 20.5 1.3 ± 26.5 −3.2 (−11.7, 5.3)
Flatus 2.2 ± 37.8 2.0 ± 36.0 −0.2 (−13.2, 12.8)
Mean change in IIQ scores
IIQ Physical −10.6 ± 26.4 −13.5 ± 26.4 −2.9 (−12.4, 6.5)
Mobility −5.6 ± 24.3 −9.3 ± 22.9 −3.7 (−11.8, 4.6)
Social −5.0 ± 19.6 −8.4 ± 22.6 −3.4 (−11.2, 4.6)
Embarrassment −0.9 ± 20.6 −0.5 ± 23.4 0.4 (−7.6, 8.4)
Emotional −3.6 ± 25.4 −4.8 ± 24.3 −1.2 (−10.0, 7.6)
Mean change in PISQ-12 scores 0.0 ± 4.2 2.9 ± 6.8 −2.9 (−6.8, 1.1)
Data presented as mean (domain baseline scores minus corresponding 7-year domain scores) ± standard deviation
(SD). Negative scores in change reflect reduction in bother and improved quality of life compared with baseline
UDI Urogenital Distress Inventory, DDI Defecatory Distress Inventory, IIQ Incontinence Impact Questionnaire
(0–00), PISQ-12 Prolapse and Incontinence Sexual Questionnaire short form (positive change from baseline
indicates better sexual function).
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Appendix 3
Table 7 Results per vaginal
compartment at 7 years Results per vaginal compartment
Anterior compartment (level II treatment) Anterior mesh Anterior colporrhaphy
Reoperation POP anterior compartment 0/32 (0) 3/39 (8) −8 (−16, 1)
POP ≥ stage II anterior compartment 8/32 (25) 25/39 (64) −39* (−60, −18)
Reoperation POP and/or POP ≥ stage II 8/32 (25) 27/39 (69) −44* (−65, −23)
POP > hymen anterior compartment 3/32 (9) 8/39 (20) −11 (−27, 5)
Reoperation POP and/or POP > hymen 3/32 (9) 11/39 (28) −19* (−36, −2)
Composite success
• Anterior mesh only (level II) 14/24 (58)
• Anterior & total mesh (level II + I) 22/35 (63) 18/40 (45) 18 (−4, 40)
Apical compartment (level I treatment) Apical mesh Native tissue
Reoperation for POP apical compartment 0/11 (0) 3/34 (9) −9* (−11, −4)
POP ≥ II apical compartment 1/11 (9) 1/34 (3) 6 (−12, 24)
Reoperation POP and/or POP-Q ≥ II 1/11 (9) 4/34 (12) −3 (−23, 18)
POP apical compartment > hymen 1/11 (9) 1/34 (3) 6 (−12, 24)
Reoperation POP and/or POP > hymen 1/11 (9) 3/34 (9) 0 (−19, 20)
Composite success 8/11 (73) 16/36 (44) 29 (−3, 60)
Posterior compartment (level II treatment) Mesh Colporrhaphy
Reoperation POP posterior compartment 1/32 (3) 5/45 (11) −8 (−19, 3)
POP ≥ II posterior compartment 4/32 (12) 13/43 (30) −18 (−36, 0)
Reoperation POP and/or POP-Q ≥ II 4/32 (12) 18/45 (40) −28* (−46, −9)
POP posterior compartment > hymen 1/32 (3) 1/43 (2) 1 (−7, 8)
Reoperation POP and/or POP > hymen 2/32 (6) 6/45 (13) −7 (−20, 6)
Composite success
• Posterior mesh only (level II) 9/23 (39)
• Posterior and total mesh (level II + I) 17/34 (50) 25/45 (56) −6 (−28, 17)
Data presented as n (%), n (%, 95% CI), or % (95% CI)
POP pelvic organ prolapse
*This difference would be statistically significant if tested at a significance level of 0.05
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Appendix 4
Table 8 Adverse events at
7 years Mesh Native tissue Risk difference (95% CI)
De novo SUI 12/62 (19) 8/66 (12) 7 (−5, 20)
Graft-related adverse eventsa
• Exposure 22/53 (42) 4/67 (6)b 36* (21, 50)
• Retraction mesh during examination 17/53 (32) 2/67 (3) 29* (16, 42)
• Reoperation for complication 8/53 (15) 4/68 (6) 9 (−2, 20)
• Reoperation for exposure 7/53 (13) 0/68 (0) 13* (4, 22)
Pain and dyspareunia
Indicated at the outpatient visit
Pain 8 (15) 20 (30) −15 (−30, 0)
Dyspareunia 14 (26) 15 (22) 4 (−12, 20)
Pain and/or dyspareunia 17 (32) 29 (43) −11 (−28, 6)
Location of pain
• Vulvar 1 (6) 2 (7) −1 (−16, 14)
• Vaginal 1 (6) 5 (17) −11 (−29, 6)
• Lower abdomen 4 (24) 8 (28) −4 (−30, 22)
• Lower back 0 (0) 4 (14) −14 (−26, 0)
• Other 11 (65) 10 (34) 29* (2, 59)
VAS (spontaneous pain) 1.4 ± 2.3 2.0 ± 2.3 −0.6 (−2.0, 0.8)
VAS (during physical activity) 2.0 ± 3.1 2.3 ± 2.5 −0.3 (−2.0, 1.4)
VAS (during sexual intercourse) 4.6 ± 3.6 2.7 ± 3.3 1.9 (−0.2, 4.0)
During gynecological examination
Provoked pain 24 (45) 16 (24) 21* (5, 38)
• Apical 12 (50) 11 (69) −19 (−49, 12)
• Mesh arms (distal/proximal) 8 (33) 2 (12) 21 (−4, 46)
• Deep ligament 1 (4) 1 (6) −2 (−16, 12)
• Other 3 (12) 2 (12) 0 (−21, 21)
VAS (patient) 5.2 ± 2.1 5.3 ± 2.2 −0.1 (−1.5, 1.3)
VAS (subjective impression of examiner) 5.3 ± 2.2 4.8 ± 2.1 0.5 (−0.9, 1.9)
Indicated on questionnaire
Dyspareunia during sexual intercourse 13/64 (20) 12/72 (17) 3 (−9, 17)
• Somewhat 5 (38) 6 (50) −12 (−50, 27)
• Moderately 4 (31) 4 (33) −2 (−39, 34)
• Quite a bit 4 (31) 2 (17) 14 (−19, 47)
Data presented as numbers (%) or mean ± standard deviation (SD) and mean (95% CI)
SUI stress urinary incontinence, VAS visual analog scale, CI confidence interval
a Cumulative up to 7 years; more details on graft-related adverse events and morbidity are shown in the
BAddendum^
b Exposure of Prolene thread in sacrospinous ligament fixation (1), exposure after midurethral sling for inconti-
nence (1), exposures of mesh inserted for POP recurrence after index surgery (2)
*This difference would be statistically significant if tested at a significance level of 0.05
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